Quarterly Report Q1 2018: Helix BioPharma Loss increases 9.3% Corporate Wire Date: 31 December 2018 22:58 EST
Helix BioPharma (TSX:HBP) announced loss for the quarter-ended 31 October 2018 of CAD1.4m ($US1.1m), up 9.3% from CAD67.0m ($US51.0m) in the previous corresponding period.
Major changes compared with previous corresponding period [Year-on-Year]:
- Loss of CAD1.4m ($US1.1m)
Per Share figuresOctober 312018201720182017Change (%)DescriptionCADCAD$US$USEPS(1c)(2c)(US0.8c)(US1.6c)Improvement